6WXN

EGFR(T790M/V948R) in complex with LN3844

Summary for 6WXN

• Entry DOI: 10.2210/pdb6wxn/pdb
• Descriptor: Epidermal growth factor receptor, N-(3-{5-[2-(acetylamino)pyridin-4-yl]-2-(methylsulfanyl)-1H-imidazol-4-yl}phenyl)-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-6-fluoro-3-hydroxybenzamide, PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER, ... (6 entities in total)
• Functional Keywords: cancer, inhibitor, transferase, transferase-transferase inhibitor complex, transferase/transferase inhibitor
• Biological source: Homo sapiens (Human)
• Total number of polymer chains: 4
• Total formula weight: 151756.73

Authors

Heppner, D.E.,Eck, M.J. (deposition date: 2020-05-11, release date: 2021-05-19, Last modification date: 2023-10-18)

Primary citation

Wittlinger, F.,Heppner, D.E.,To, C.,Gunther, M.,Shin, B.H.,Rana, J.K.,Schmoker, A.M.,Beyett, T.S.,Berger, L.M.,Berger, B.T.,Bauer, N.,Vasta, J.D.,Corona, C.R.,Robers, M.B.,Knapp, S.,Janne, P.A.,Eck, M.J.,Laufer, S.A.
Design of a "Two-in-One" Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric Sites.
J.Med.Chem., 65:1370-1383, 2022

PubMed Abstract: Inhibitors targeting the epidermal growth factor receptor (EGFR) are an effective therapy for patients with non-small cell lung cancer harboring drug-sensitive activating mutations in the EGFR kinase domain. Drug resistance due to treatment-acquired mutations has motivated the development of successive generations of inhibitors that bind in the ATP site. The third-generation agent osimertinib is now a first-line treatment for this disease. Recently, allosteric inhibitors have been developed to overcome drug-resistant mutations that confer a resistance to osimertinib. Here, we present the structure-guided design and synthesis of a mutant-selective lead compound, which consists of a pyridinyl imidazole-fused benzylisoindolinedione scaffold that simultaneously occupies the orthosteric and allosteric sites. The compound potently inhibits enzymatic activity in L858R/T790M/C797S mutant EGFR (4.9 nM), with a significantly lower activity for wild-type EGFR (47 nM). Additionally, this compound achieves modest cetuximab-independent and mutant-selective cellular efficacies on the L858R (1.2 μM) and L858R/T790M (4.4 μM) variants.

PubMed: 34668706
DOI: 10.1021/acs.jmedchem.1c00848

Experimental method

X-RAY DIFFRACTION (1.76 Å)